Abstract
A new class III antiarrhythmic drug niferidil has been recently introduced as a highly effective therapy cure for cases of persistent atrial fibrillation, but ionic mechanisms of its action are still unknown. Effects of niferidil on action potential (AP) waveform and major ionic currents were studied in mouse ventricular myocardium. APs were recorded with glass microelectrodes in multicellular preparations of right ventricular wall. Whole-cell patch-clamp technique was used to measure K+, Ca2+, and Na+ currents in isolated mouse ventricular myocytes. While 10−7 M niferidil failed to alter the AP configuration, 10−6 M tended to prolong APs (by 12.05 ± 1.8 % at 50 % of repolarization) and 10−5 M induced significant slowing of repolarization (32.1 ± 4.9 % at 50 % of repolarization). Among the potassium currents responsible for AP repolarization phase, I K1 was found to be almost insensitive to niferidil. I to demonstrated low sensitivity to niferidil with IC50 = 2.03 × 10−4 M. I Kur, which was previously hypothesized to be the main target of the drug, was more sensitive with IC50 = 6 × 10−5 M. However, sustained delayed rectifier potassium current I ss was inhibited with even lower IC50 = 2.8 × 10−5 M. Therefore, suppression of I ss and, second, I Kur by niferidil seems to underlie the AP prolongation in mouse ventricular tissue. Niferidil also produced a modest decrease in I CaL peak amplitude (IC50≈10−4 M), but failed to alter I Na significantly. Niferidil prolongs APs in mouse ventricular myocardium mainly by inhibiting I ss and I Kur K+ currents, but not exclusively I Kur, as was proposed earlier. Further investigations are required to reveal the mechanisms of niferidil action in human myocardium, where I Kr is strongly expressed instead of I ss.
Similar content being viewed by others
References
Brouillette J, Clark RB, Giles WR, Fiset C (2004) Functional properties of K+ currents in adult mouse ventricular myocytes. J Physiol 559:777–798
Camm AJ, Lip GYH, Caterina R, Savelieva I, et al (2012) ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 33:2719–2747
Fedorov VV, Sharifov OF, Beloshapko GG, Yushmanova AV, Rosenshtraukh LV (2000) Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation. J Cardiovasc Pharmacol 36:77–89
Fedorov VV, Rosenshtraukh LV, Reznik AV, et al (2004) Antiarrhythmic efficacy of a new class III antiarrhythmic drug RG-2. Kardiologiia 44:66–74
Finnin M (2010) Vernakalant: a novel agent for the termination of atrial fibrillation. Am J Health Syst Pharm 67:1157–1164
Glushkov RG, Yuzhakov SD, L’vov AI, et al (2011) New group of class III antiarrhythmic drugs: piperid-4-ylethane derivatives. Pharm Chem J 45:3–12
Golitsyn SP, Yuricheva YA, Maykov EB, et al (2011) Intravenous niferidil, a new class III antiarrhythmic agent, for termination of persistent atrial fibrillation and flutter. Circulation 124:A10356 Abstract
Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y (2010) Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev 90:291–366
Isenberg G, Klockner U (1982) Calcium tolerant ventricular myocytes prepared by preincubation in a ‘KB-medium’. Pflugers Arch 395:6–18
Jahnel U, Klemm P, Nawrath H (1994) Different mechanisms of the inhibition of the transient outward current in rat ventricular myocytes. Naunyn Schmiedeberg's Arch Pharmacol 349:87–94
Kamkin A, Kiseleva I, Isenberg G (2000) Stretch-activated currents in ventricular myocytes: amplitude and arrhythmogenic effects increase with hypertrophy. Cardiovasc Res 48:409–420
Li GR, Feng J, Yue L, Carrier M, Nattel S (1996) Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res 78:689–696
Liu GX, Zhou J, Koren G (2008) Single-channel properties of IK,slow1 and IK,slow2 in mouse ventricular myocytes. Pflugers Arch - Eur J Physiol 456:541–547
Mashkovsky MD, Glushkov RG, Dorodnikova SD, et al (1995) The search for antiarrhythmic drug among the derivatives of 1,5-diaminopentane. Khim Farm Zh 3:27–31
Maykov EB, Yuricheva YA, Mironov NY, et al (2014) Efficacy of a new class III drug niferidil in cardioversion of persistent atrial fibrillation and flutter. J Cardiovasc Pharmacol 64:247–255
Nattel S, Yue L, Wang Z (1999) Cardiac ultrarapid delayed rectifiers: a novel potassium current family of functional similarity and molecular diversity. Cell Physiol Biochem 9:217–226
Regan CP, Kiss L, Stump GL, et al (2008) Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2 H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure. J Pharmacol Exp Ther 324:322–330
Reisinger J, Gatterer E, Lang W, et al (2004) Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 25:1318–1324
Reznik AV, Fedorov VV, Kokoz YM, et al (2003) Ionic mechanisms of cardiotropic action of a new class III antiarrhythmic drug RG-2. Kardiologiia 43:76–82
Rosenshtraukh LV, Fedorov VV, Reznik AV, et al (2003) Electrophysiological experimental study of a novel class III antiarrhythmic drug RG-2. Kardiologiia 43:56–63
Sridhar A, da Cunha DN, Lacombe VA, et al (2007) The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization. Br J Pharmacol 152:870–879
Xu H, Guo W, Nerbonne JM (1999) Four kinetically distinct depolarization-activated K+ currents in adult mouse ventricular myocytes. J Gen Physiol 113:661–677
Zhang X, Anderson JW, Fedida D (1997) Characterization of nifedipine block of the human heart delayed rectifier, hKv1.5. J Pharmacol Exp Ther 281:1247–1256
Acknowledgments
This study was supported by Russian Science Foundation (RSF) 14-15-00268 for DVA and Russian Foundation for Basic Research (RFBR) 14-04-01781 for LVR.
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abramochkin, D.V., Kuzmin, V.S. & Rosenshtraukh, L.V. Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms. Naunyn-Schmiedeberg's Arch Pharmacol 388, 1105–1112 (2015). https://doi.org/10.1007/s00210-015-1146-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-015-1146-x